Keyphrases
Multiple Myeloma
100%
Cytotoxicity
100%
Novel Agents
100%
Growth in Vitro
100%
Halofuginone
100%
Myeloma Cells
36%
Phosphorylation
18%
Conventional Therapy
18%
Doxorubicin
9%
Mitochondrial Membrane Potential
9%
Lenalidomide
9%
High Dose
9%
CD40
9%
Interleukin-6
9%
Growth Factors
9%
Malignancy
9%
Peripheral Blood Mononuclear Cells
9%
Caspase-3
9%
Induced Apoptosis
9%
P38 Mitogen-activated Protein Kinase (p38 MAPK)
9%
Antitumor Activity
9%
Anticancer Activity
9%
Signaling Cascades
9%
Anti-apoptotic Proteins
9%
C-Jun N-terminal Kinase
9%
Insulin-like
9%
Apoptotic Cell Death
9%
Myeloma
9%
Melphalan
9%
Novel Therapies
9%
C-Jun
9%
Synthetic Derivatives
9%
Caspase-8
9%
Plasma Cells
9%
Patient-derived
9%
Caspase-9
9%
Human Mesenchymal Stem Cells (hMSCs)
9%
Heat Shock Protein 27 (HSP27)
9%
Activity in Vivo
9%
Myeloid Cell leukemia-1 (Mcl-1)
9%
Xenograft Mouse Model
9%
Multiplex Analysis
9%
Quinazolinone Alkaloids
9%
Poly(ADP-ribose) Polymerase
9%
G(0)
9%
Synergistic Cytotoxicity
9%
Medicine and Dentistry
In Vitro
100%
Multiple Myeloma
100%
Cytotoxicity
100%
Halofuginone
100%
Myeloma Cell
27%
Programmed Cell Death
18%
Antineoplastic Activity
18%
Lenalidomide
9%
Myeloma
9%
Drug Megadose
9%
Melphalan
9%
Dexamethasone
9%
Interleukin 6
9%
Cancer
9%
Clinical Study
9%
Peripheral Blood Mononuclear Cell
9%
Xenograft
9%
Cell Cycle
9%
Antiapoptotic
9%
Downregulation
9%
Somatomedin C
9%
Mitochondrial Membrane Potential
9%
Protein P53
9%
Doxorubicin
9%
Phosphotransferase
9%
Plasma Cell
9%
Caspase 9
9%
Caspase 8
9%
Caspase 3
9%
Bone Marrow Stromal Cell
9%
Multiple Myeloma Cell Line
9%
Poly ADP Ribose Polymerase
9%
Quinazolinone Derivative
9%
Immunology and Microbiology
Multiple Myeloma
100%
Cytotoxicity
100%
Myeloma Cell
50%
Antineoplastic Activity
33%
Lenalidomide
16%
Downregulation
16%
Mouse Model
16%
P53
16%
Caspase
16%
Interleukin 6
16%
Peripheral Blood Mononuclear Cell
16%
Xenograft
16%
Drug Megadose
16%
Cell Cycle
16%
Apoptosis
16%
Mitochondrial Membrane Potential
16%
Preclinical Study
16%
Dexamethasone
16%
Somatomedin C
16%
Plasma Cell
16%
Multiple Myeloma Cell Line
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Cytotoxicity
100%
Halofuginone
100%
Myeloma
18%
Neoplasm
9%
Doxorubicin
9%
Clinical Study
9%
Malignant Neoplasm
9%
Lenalidomide
9%
Phosphotransferase
9%
Mouse Model
9%
Dexamethasone
9%
Interleukin 6
9%
Preclinical Study
9%
Caspase 3
9%
Antiapoptotic
9%
Somatomedin C
9%
Caspase 8
9%
Melphalan
9%
Protein P53
9%
Caspase 9
9%
Quinazolinone Derivative
9%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
9%